CYTOKINETICS, INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.9 USD | +0.71% |
|
+2.12% | -35.44% |
| 24/06 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
| 17/06 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
Presenter SpeechKyuwon Choi (Analysts)[Operator Instructions] I'm Paul Choi, and I cover the S...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Its cardiac muscle contractility program is focused on the cardiac sarcomere. Its clinical-stage drug candidates are: aficamten, which is a next-in-class cardiac myosin inhibitor; omecamtiv mecarbil, which is a cardiac myosin activator; CK-586, which is an additional cardiac myosin inhibitor, and CK-136, which is a cardiac troponin activator. CK-586 is designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction.
Calendar
01/08/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
53.9
USD
Average target price
82.65
USD
Spread / Average Target
+53.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.44% | 626.34Cr | |
| +16.73% | 12TCr | |
| +21.13% | 11TCr | |
| +20.29% | 2.59TCr | |
| -17.94% | 2.09TCr | |
| -16.24% | 1.65TCr | |
| -11.76% | 1.68TCr | |
| -44.45% | 1.56TCr | |
| +69.92% | 1.55TCr | |
| +1.41% | 1.34TCr |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- Transcript : Cytokinetics, Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 11
